Daily Endocrinology Research Analysis
Analyzed 30 papers and selected 3 impactful papers.
Summary
Three studies shape today’s endocrinology landscape: an IPD meta-analysis links lower circulating androgens to higher cancer mortality in men; a large real-world comparative study suggests semaglutide may outperform SGLT2 inhibitors across cardiohepatic-renal outcomes in MASLD; and an early-phase randomized trial of a new long-acting GLP-1 analog (GZR18) shows meaningful HbA1c and weight reductions with good tolerability.
Research Themes
- Cardiometabolic therapeutics and outcome optimization in MASLD
- Sex hormones as biomarkers for oncologic risk in men
- Next-generation incretin therapies for type 2 diabetes
Selected Articles
1. Associations of testosterone, sex hormone-binding globulin, and related hormones with risks of cancer death, incident cancer, and incident prostate cancer in men: individual participant data meta-analyses.
Across 10 prospective cohorts with IPD, lower total testosterone and dihydrotestosterone were associated with higher cancer mortality in men, with risk increasing below approximately 8.6 nmol/L. Mid-range SHBG and LH were linked to the lowest cancer death risk, while lower SHBG or LH—rather than testosterone—predicted higher incident prostate cancer risk.
Impact: Provides robust, adjusted IPD evidence linking endogenous sex hormones to cancer outcomes, suggesting hormone panels could refine risk stratification beyond traditional factors.
Clinical Implications: Men with very low testosterone and low SHBG/LH may warrant closer oncologic surveillance; hormone profiles could inform personalized risk discussions, though causality and management thresholds require further study.
Key Findings
- Lower total testosterone associated with higher cancer mortality (Q1 vs Q5 HR 1.18, 95% CI 1.04–1.34).
- Lower dihydrotestosterone associated with higher cancer mortality (Q1 vs Q5 HR 1.21, 95% CI 1.06–1.38).
- Mid-range SHBG and LH linked to the lowest cancer death risk; lower SHBG or LH predicted higher incident prostate cancer, while testosterone did not.
- Increased incident cancer risk at very low testosterone (<7.3 nmol/L).
Methodological Strengths
- Individual participant data meta-analysis of prospective cohorts with mass spectrometry hormone assays
- Pre-registered, multivariable-adjusted two-stage random-effects models with comprehensive confounder control
Limitations
- Observational cohorts cannot establish causality; residual confounding possible
- Heterogeneity in cohort populations and assay timing; thresholds need external validation
Future Directions: Prospective intervention studies to test whether modifying very low androgen or SHBG/LH states alters cancer outcomes; validation of risk thresholds and integration into multifactorial prediction tools.
BACKGROUND: Whether differences in sex hormones influence cancer risk in men remains uncertain. We aimed to clarify the association of circulating testosterone, sex hormone-binding globulin (SHBG), and related hormones with risks of cancer death, incident cancer, and incident prostate cancer by means of individual participant data (IPD) meta-analyses. METHODS: A systematic review of the literature using MEDLINE, Embase, OpenGrey, and Mednar was conducted from date of database inception till July 22, 2019, with bridge searches using MEDLINE till Jan 21, 2026. Prospective cohort studies comprising 1000 or more community-dwelling men with testosterone concentrations measured using mass spectrometry and a follow-up of 5 years or more were included. Two-stage random-effects meta-analyses were performed, controlling for baseline age, previous cancer, BMI, marital status, alcohol consumption, smoking status, physical activity, hypertension status, and diabetes status. Risk of bias was assessed using the Newcastle-Ottawa method. This study was prospectively registered with PROSPERO (CRD42019139668). FINDINGS: Ten studies provided IPD (24 510 men; 276 931 participant-years; 2847 cancer deaths), and one provided aggregate data (1535 men; 184 cancer deaths). Five studies provided IPD for incident prostate cancer (12 280 men; 151 373 participant-years; 918 events). Lower total testosterone concentrations were associated with higher risk of cancer death (median of first vs median of fifth quintile [Q1:Q5] hazard ratio [HR] 1·18, 95% CI 1·04-1·34), as were lower dihydrotestosterone concentrations (Q1:Q5 1·21, 1·06-1·38), the risk increasing with testosterone concentrations less than 8.6 nmol/L. SHBG and luteinising hormone concentrations were non-linearly associated with risk of cancer death (lowest risk: SHBG Q3:Q5 HR 0·81, 95% CI 0·68-0·97; luteinising hormone Q2:Q5 0·73, 0·59-0·90). Men with very low baseline testosterone concentrations had a higher risk of incident cancer, the risk increasing with concentrations less than 7.3 nmol/L. Lower SHBG or lower luteinising hormone concentrations were associated with higher risk of incident prostate cancer (Q1:Q5 HR 1·28, 95% CI 1·07-1·54; Q1:Q5 1·45, 1·13-1·86); testosterone was not associated with this outcome. Estimates of I INTERPRETATION: Lower total testosterone or dihydrotestosterone concentrations in men were associated with a higher risk of cancer death, and mid-range SHBG or luteinising hormone concentrations were associated with a lower risk. Men with lower SHBG or luteinising hormone concentrations had an associated higher risk of incident prostate cancer. Sex hormones could serve as biomarkers for cancer risk, warranting further investigation of these observed associations. FUNDING: Medical Research Future Fund; Government of Western Australia; Lawley Pharmaceuticals.
2. Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial.
In a randomized, double-blind, placebo-controlled phase 1b/2a trial (n=72), once-weekly GZR18 produced significant HbA1c reductions (up to −1.81%) and weight improvements over 23–26 weeks, with mostly mild-to-moderate GI adverse events and no treatment-related serious events.
Impact: Demonstrates clinically meaningful glycemic and weight benefits with a novel long-acting GLP-1 analog, informing next-generation incretin therapy development.
Clinical Implications: If confirmed in larger phase 3 trials, once-weekly GZR18 could expand GLP-1 RA options for T2DM with favorable efficacy and tolerability; nutritional and exercise support remain essential to preserve lean mass.
Key Findings
- HbA1c reductions versus placebo in both parts (Part A: −1.32% vs 0.86%; Part B: −1.81% vs 0.12%).
- Weight and metabolic parameters improved over 23–26 weeks.
- Safety profile acceptable: mainly mild–moderate GI events; no severe hypoglycemia or treatment-related serious AEs.
Methodological Strengths
- Randomized, double-blind, placebo-controlled design across two titration regimens
- Clinically relevant endpoints (HbA1c, weight) with 23–26-week follow-up
Limitations
- Early-phase trial with small sample size and limited duration
- Single-country population; no active comparator against approved GLP-1 RAs
Future Directions: Phase 2/3 head-to-head trials versus established GLP-1 RAs and SGLT2 inhibitors, assessment of cardiovascular, renal, and hepatic outcomes, and evaluation in diverse populations.
GZR18 is a long-acting glucagon-like peptide-1 receptor agonist that is under development for the treatment of type 2 diabetes mellitus (T2DM). In this randomized, double-blind, placebo-controlled phase 1b/2a trial in Chinese adults with T2DM, the safety and efficacy of once-weekly GZR18 are evaluated using different dose-titration regimens in two separate parts: Part A (0.5-4 mg over 26 weeks) and Part B (1.5-13 mg over 23 weeks). Overall, 72 participants are enrolled, of whom 62 complete the trial. GZR18 significantly reduces glycated hemoglobin (HbA1c) in both parts (Part A: -1.32% for GZR18 versus 0.86% for placebo; Part B: -1.81% for GZR18 versus 0.12% for placebo). Improvements in body weight and other metabolic parameters are also observed. GZR18 is safe and well tolerated, with mostly mild-to-moderate gastrointestinal adverse events; no severe hypoglycemia or treatment-related serious adverse events occurred. These findings support further development of GZR18 in larger, longer-term trials. The trial is registered at ClinicalTrials.gov (NCT06256523).
3. Efficacy of Initiation of Semaglutide versus SGLT2 inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Multicenter Propensity-Matched Real-World Study.
In 111,050 propensity-matched MASLD patients, semaglutide initiation was associated with lower risks of all-cause mortality, hospitalization, MACE, and MALO at 1 and 5 years versus SGLT2 inhibitors; kidney outcomes converged by 1 year but favored semaglutide by 5 years.
Impact: Provides the largest real-world head-to-head comparison of semaglutide versus SGLT2 inhibitors in MASLD, indicating broad cardiohepatic-renal benefits with semaglutide.
Clinical Implications: For MASLD patients with metabolic comorbidities, semaglutide may be a preferred first-line incretin therapy when aiming to improve mortality and multi-organ outcomes; confirmatory RCTs with histologic endpoints are needed.
Key Findings
- At 1 year, semaglutide vs SGLT2i: mortality HR 0.382, hospitalization HR 0.444, MACE HR 0.502, MALO HR 0.361.
- At 5 years, sustained advantages: mortality HR 0.494, hospitalization HR 0.565, MACE HR 0.584, MALO HR 0.494.
- MAKE neutral at 1 year (HR 0.998) but reduced at 5 years (HR 0.858).
Methodological Strengths
- Very large multicenter dataset with 1:1 propensity score matching across >50 covariates
- Time-to-event analyses with both 1-year and 5-year horizons across cardiohepatic-renal endpoints
Limitations
- Observational design with potential residual confounding and channeling bias
- Medication dose, adherence, and histologic liver outcomes not captured
Future Directions: Pragmatic and explanatory RCTs comparing semaglutide and SGLT2 inhibitors in MASLD with biopsy or imaging-based NASH/fibrosis endpoints and mechanistic cardiometabolic profiling.
OBJECTIVES: Metabolic dysfunction-associated steatotic liver disease (MASLD) is common and linked to cardiometabolic comorbidities, with few direct comparisons between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is). METHODS: This multicenter, retrospective, propensity score-matched cohort study utilized data from the TriNetX U.S. Collaborative Network. Adults with MASLD and at least one metabolic comorbidity were identified as new initiators of semaglutide (n=128,332) or SGLT2is (n=100,542), excluding alternative exposures and confounding liver etiologies. One-to-one propensity score matching on >50 covariates yielded balanced cohorts of 55,525 patients each. Time-to-event outcomes, including all-cause mortality, hospitalization, major adverse cardiovascular events (MACE), major adverse liver outcomes (MALO), major adverse kidney events (MAKE), ascites, hepatic failure, and hepatic encephalopathy, were evaluated at 1-year and 5-year follow-ups using Kaplan-Meier analysis and Cox proportional hazards models. RESULTS: Semaglutide was linked to significant risk reductions compared to SGLT2is. At 1-year, hazard ratios (HRs) were 0.382 (95% CI 0.338-0.430) for all-cause mortality, 0.444 (95% CI 0.429-0.459) for all-cause hospitalization, 0.502 (95% CI 0.476-0.530) for MACE, and 0.361 (95% CI 0.316-0.412) for MALO. At 5-years, the corresponding HRs were 0.494 (95% CI 0.459-0.531), 0.565 (95% CI 0.551-0.579), 0.584 (95% CI 0.560-0.609), and 0.494 (95% CI 0.452-0.540). MAKE showed no difference at 1-year (HR 0.998), but a reduction at 5-years (HR 0.858; 95% CI 0.789-0.933). Individual liver events (ascites, hepatic failure) followed similar patterns. CONCLUSIONS: In this large real-world MASLD cohort, initiating semaglutide was linked to potential reductions in mortality, hospitalization, and adverse cardiometabolic, liver, and kidney outcomes compared to SGLT2is.